Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2004, p. 2483-2489, Vol. 48, No. 7
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.7.2483-2489.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Candida glabrata erg1 Mutant with Increased Sensitivity to Azoles and to Low Oxygen Tension
Huei-Fung Tsai,1 Martin Bard,2 Koichi Izumikawa,1 Anna A. Krol,1 Aaron M. Sturm,2 Nicholas T. Culbertson,2 Charles A. Pierson,2 and John E. Bennett1*
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1
Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, Indiana 462022
Received 8 January 2004/
Returned for modification 10 March 2004/
Accepted 18 March 2004

ABSTRACT
A
Candida glabrata erg1 (
Cgerg1) mutant, CgTn201S, was identified
by transposon mutagenesis and by increased fluconazole susceptibility.
CgERG1 encodes a 489-amino-acid protein which, on the basis
of its homology with
Saccharomyces cerevisiae ERG1, is a squalene
epoxidase essential for ergosterol synthesis. Interruption following
codon 475 of CgErg1p decreased the ergosterol content by 50%;
caused accumulation of the squalene precursor; increased the
levels of susceptibility to fluconazole, itraconazole, and terbinafine;
increased the level of resistance to amphotericin B; increased
the levels of rhodamine 6G and [
3H]-fluconazole uptake; reduced
the level of growth; and blocked growth under conditions of
low oxygen tension. In addition, CgTn201S efficiently took up
exogenous cholesterol from cholesterol-containing serum. Cholesterol
constituted 34% of the extractable sterols in CgTn201S when
it was grown aerobically on serum-containing medium. Under the
same conditions,
C. albicans contained only 0.1 to 1.2% cholesterol.
Exogenous sterols also restored growth under conditions of low
oxygen tension. Finally, complementation of the
Cgerg1 mutation
restored the levels of [
3H]fluconazole uptake and drug susceptibility
to wild-type levels.

INTRODUCTION
Transposon-based insertion into
Candida glabrata has been used
effectively for mutational analysis (
3). We adapted a commercial
Tn
5-based system for insertion of Tn
5 into
C. glabrata genomic
DNA. After rescue cloning of the Tn
5 DNA from the
C. glabrata transformants with increased fluconazole susceptibilities, we
found that one of the fluconazole-susceptible transformants,
CgTn201S, had an insertion in the 3' end of the
C. glabrata ERG1 (
CgERG1) open reading frame (ORF). We explored the mechanism
by which this mutation causes fluconazole susceptibility because
of our interest in azole resistance in this species. Prolonged
treatment of patients with fluconazole causes substantial increases
in the levels of azole resistance in
C. glabrata. This species
is naturally about 8-fold more resistant to fluconazole than
Candida albicans, and following drug exposure, the levels of
resistance can increase 16-fold more, leading to clinically
significant fluconazole resistance (
1,
18). The major mechanisms
for clinical resistance described to date have been increased
drug efflux and alteration of the azole-binding site, the C-14
sterol demethylase, coded for by
ERG11. Recently, an
erg1C1228G Saccharomyces cerevisiae mutant was reported to be aerobically
viable and to have at least a 10-fold increase in the level
of terbinafine resistance but no change in the level of itraconazole
resistance (
9). Null
erg1 mutants of
S. cerevisiae are not aerobically
viable but are anaerobically viable in the presence of exogenous
ergosterol (
11). In the absence of data about
Cgerg1 mutants,
we studied the phenotype of strain CgTn201S, including its azole
susceptibility, its ability to grow under conditions of low
oxygen tension, and its uptake of exogenous sterols.

MATERIALS AND METHODS
Strains and culture conditions.
Plasmids were maintained in
Escherichia coli XL1-Blue (Stratagene,
La Jolla, Calif.) and Top 10F' (Invitrogen, Carlsbad, Calif.)
host cells grown in the presence of 50 µg of ampicillin
per ml or 12.5 µg of chloramphenicol per ml. EC100D
pir+ and EC100D
pir-
116 (Epicentre, Madison, Wis.) were used as hosts
for the EZ::TN transposon (Epicentre), the replication of which
is reliant on the R6K origin.
C. glabrata strains (Table
1)
were cultured on either YPD agar, which contained 1% Bacto Yeast
Extract (Difco Laboratories, Detroit, Mich.), 2% Bacto Peptone
(Difco), and 2% glucose (Sigma, St. Louis, Mo.), or MIN agar,
which contained 0.67% Yeast Nitrogen Base plus 2% glucose without
amino acids (Difco).
C. glabrata ura3 mutants were selected
on MIN agar containing 1 mg of 5-fluoroorotic acid (FOA; Lancaster,
Pelham, N.H.) per ml and 50 µg of uracil per ml; and the
genotype was confirmed by the restoration of uracil prototrophy
with
S. cerevisiae URA3 from YEp24 (
2).
C. albicans was grown
on YPADU (1% Bacto Yeast Extract, 2% Bacto Peptone, 2%
D-glucose,
0.12% adenine, 0.8% uridine [Sigma]). YPADU containing 20% bovine
serum (Sigma) or 20 µg of sterol (ergosterol or cholesterol)
per ml was used for sterol uptake analysis. The GasPak Plus
system (BBL Microbiology Systems, Cockeysville, Md.) or the
BBL GasPak Pouch anaerobic system (BBL Microbiology Systems)
was used for cultures grown under conditions of low oxygen tension
(hypoxic).
Fluconazole susceptibility was determined by Etest (AB Biodisk,
Solna, Sweden) on YPD agar. Two milligrams of ergosterol or
cholesterol was dissolved in a mixture of 50% ethanol and 50%
Tween 80 (Sigma) to give a 2-mg/ml stock solution, which was
used to supplement the media with a final sterol concentration
of 20 µg/ml. For comparison, the same final concentration
of ethanol-Tween 80 without sterol was used. The susceptibilities
of the strain to fluconazole (courtesy Pfizer, Sandwich, United
Kingdom), itraconazole (Janssen Pharmaceuticals, Titusville,
N.J.), amphotericin B (Pharma-Tek, Huntington, N.Y.), and terbinafine
(courtesy of Neil Ryder, Novartis, Vienna, Austria) were tested.
The MICs for 80% growth reduction (MIC
80) were determined by
the NCCLS method, modified by addition of glucose 2% to the
RPMI medium and incubation at 37°C or with MIN medium at
30°C.
To evaluate the ability of C. glabrata to utilize exogenous sterols, cells were inoculated into 50 ml of liquid medium and incubated at 30°C with shaking at 200 rpm overnight. The cell concentration was counted under a microscope with a hemacytometer and then diluted to give a series cell concentrations of 2 x 107, 2 x 106, 2 x 105, and 2 x 104 cells/ml. Five microliters of each concentration was added onto solid medium to give a series of spots containing 105 to 102 cells.
Construction of a C. glabrata genomic fosmid library.
Large fragments of C. glabrata genomic DNA were often found to be unstable in E. coli when they were maintained on a high-copy-number plasmid. Therefore, a fosmid was used for genomic library construction. To overcome the problem of poor DNA yield due to the low-copy-number fosmid, we used a copy control (CC) fosmid, which carries a second replication origin and which can be induced to replicate at high copy numbers. CC fosmid vector pCC1Fos (Epicentre) was modified by cloning a 1.2-kb HindIII DNA fragment from YEp24, which carries the S. cerevisiae URA3 gene, to give the vector pCC1URA3. Genomic DNA for the fosmid library was obtained from C. glabrata strain Cg13928, a fluconazole-resistant clinical isolate. Size-selected 40- to 60-kb fragments from the sheared genomic DNA of Cg13928 were ligated with Eco72I-digested pCC1URA3 DNA and packaged in vitro. A total of 1,600 colonies were obtained after transfection of E. coli EPI300 (Epicentre). The average insert size of the genomic library was about 40 kb.
Transposon construction, insertion, and rescue.
The custom Tn5 transposon Tn5<Cm URA3> was constructed to carry an E. coli replication origin, a chloramphenicol selection marker in E. coli, and a uracil selection marker in C. glabrata. A 1.2-kb HindIII DNA fragment carrying the S. cerevisiae URA3 gene from YEp24 was cloned into the HindIII site of EZ::TNpMOD-3<R6K
ori/MCS> (Epicentre) to give pMOD-ScURA3. Subsequently, a 1.2-kb XhoI DNA fragment carrying the chloramphenicol resistance gene from pBC KS+ (Stratagene) was blunt ended with T4 DNA polymerase and cloned into the blunt-ended BamHI site of pMOD-ScURA3 to give pMOD-CM1. The 2.9-kb custom transposon Tn5<Cm URA3> was purified from pMOD-CM1 after PshA1 digestion and was used for DNA tagging by transposase-mediated transposition in vitro.
Transposase (Epicentre) was used to mediate the in vitro insertion of Tn5<CmURA3> into the purified sheared 40- to 60-kb genomic DNA from fluconazole-resistant C. glabrata isolate Cg4672 (Fig. 1). DNA containing transposed genomic DNA from a transposon was then electroporated into intermediate fluconazole-resistant clinical isolate Cg1660u, a ura3 mutant of Cg1660. The fluconazole MIC80 for Cg1660 was 32 µg/ml by the standard NCCLS M27-A protocol (16). Tn5<Cm URA> served as both a selection marker and a mutagenic agent during C. glabrata transformation. Transformants exhibiting URA3 prototrophy were selected for altered fluconazole susceptibilities.
The genomic DNA from the mutants into which the transposon had
been inserted was digested with BglII, self-ligated, and used
to transform
E. coli EC100D
pir+ or EC100D
pir-
116 (Epicentre)
(Fig.
1). Plasmid DNA was then isolated from the
E. coli transformants
and sequenced by using transposon-specific primers SqFP and
SqRP (Epicentre). The nucleotide sequences of the DNA were then
used to search the GenBank database with the BLASTX algorithm
to identify homologs. A plasmid (pTn201S) rescued from fluconazole-susceptible
transformant CgTn201S was found to contain sequences homologous
to that of
S. cerevisiae ERG1. The full nucleotide sequence
of the
CgERG1 homolog was obtained from the Pasteur Institute
genomic database (Génolevures Consortium;
http://cbi.labri.fr/Genolevures/),
prior to publication of the complete genome sequence of
C. glabrata,
through the courtesy of Bernard Dujon and Christophe Hennequin.
Cloning of CgERG1.
A 2.2-kb CgERG1 gene was obtained by PCR with PfuUltra DNA polymerase (Stratagene), primer set CgERG1-3S (5'-TAGAGACCACTTCGGTCAAG-3') and CgERG1-4AS (5'-TTTCTATTGTGTGAGGAAATG-3'), and total DNA of strain NCCLS84 as the template. The PCR parameters were 2 min at 94°C, followed by 30 cycles of 94°C for 30 s, 53°C for 30 s, and 72°C for 2 min 30 s and then extension at 72°C for 10 min. The PCR product was then cloned into pCR-Script Amp SK(+) (Stratagene) to give plasmid pCgERG1.
CgERG1 complementation.
For functional complementation, a full-length CgERG1 gene was obtained from the C. glabrata fosmid genomic library by screening by PCR with the primer set CgERG1-3S and CgERG1-4AS. A 7-kb HindIII DNA fragment containing CgERG1 from a positive fosmid clone was blunt ended with Klenow DNA polymerase and subcloned into the SmaI site of pCgACU (a gift from K. Kitada) (8) to give pCgERG1-f2. To replace the CgERG1 gene in CgTn201S disrupted by the transposon, pCgERG1-f2 was digested with ApaI and transformed into Tn201S. Transformants were selected on MIN-uracil-100 µg of fluconazole per ml and then replicated on a MIN-uracil-FOA agar plate. FOA-resistant transformants were selected and analyzed by PCR. Southern analysis indicated that in the clone into which Cgerg1 was inserted, Cgerg1 was replaced with the CgERG1 wild-type gene by targeted gene replacement in complemented strain CgTn201C (Fig. 2).
Sterol analysis.
To measure the sterol contents of the yeast strains both qualitatively
and quantitatively, sterols were extracted from yeast cells
by saponification, as described previously (
13), and were then
analyzed by gas chromatography. An HP5890 GC series II instrument
equipped with the Hewlett-Packard CHEMSTATION software package
was used to analyze the sterol profiles. The capillary column
(DB-5) was 15 m by 0.25 mm by 0.25 µm and was programmed
to heat from 195 to 280°C (1 min at 195°C, then an increase
to 240°C at 20°C/min, and then an increase to 280°C
at 2°C/min). The linear velocity was 30 cm/s, nitrogen was
used as the carrier gas, and all injections were run in the
splitless mode (
6). To calculate the percentage of sterol per
milligram of cell mass, 10 ml of the original 250-ml culture
was harvested by vacuum filtration onto a preweighed 0.45-µm-pore-size
Whatman filter. The cells were dried in a 75°C oven overnight,
followed by desiccation at room temperature for 4 h. The amount
of each individual sterol was calculated on the basis of the
area under each peak of the chromatograph relative to the area
for a known amount of sterol standard loaded onto the gas chromatograph
by using the Hewlett-Packard sterol quantitation program. Each
sample was injected twice, and the quantity of each sterol reported
is the average from two injections.
Rhodamine 6G accumulation analysis.
The accumulation of rhodamine 6G (Sigma) was measured by flow cytometry in a FACS Calibur fluorescence-activated cell cytometer (Becton Dickinson, San Jose, Calif.) (7, 12). Cultures grown overnight at 30°C in MIN medium were diluted with MIN so that the optical density at 600 nm was 1 and were shaken for an additional 2 h at 30°C. Rhodamine 6G was added to give a final concentration of 0.2 µg/ml, and the culture was shaken for an additional 4 h at 30°C. After incubation, 10 µl of the culture was transferred to 0.9 ml of ice-cold phosphate-buffered saline (PBS) at pH 7.0 and incubated on ice for 5 min before fluorescence-activated cell sorter (FACS) analysis. A total of 20,000 cells were scanned with a 488-nm laser and an FL-2 filter. Cultures without rhodamine 6G were also analyzed and served as unstained controls. Data were analyzed with the CellQuest (Becton Dickinson) and FlowJo (Tree Star Inc., San Carols, Calif.) programs. The geometric mean fluorescence was used for calculation.
[3H]fluconazole accumulation assay.
C. glabrata was grown at 30°C overnight in MIN medium with and without 20 µg of ergosterol per ml under aerobic or low-oxygen-tension conditions. Cells were collected by centrifugation and resuspended in the same volume of MIN. The optical densities of the cell suspensions were measured to determine the number of cells used for fluconazole uptake analysis (17). Fluconazole uptake was measured by using drug that had been tritiated by gas exchange to a specific activity of 629 GBq/mmol (Amersham Biosciences, Arlington Heights, Ill.). [3H]fluconazole was added to the cell suspensions at a final concentration of 7.4 kBq/ml (0.2 µCi/ml; 3.6 ng/ml) (1). After 60 min of rotation at 225 rpm and 30°C, triplicate 2.5-ml samples were filtered on a Millipore (Bedford, Mass.) vacuum manifold by using 24-mm-diameter filters (Whatman GF/C, Maidstone, United Kingdom) which had been presoaked in 100 µM unlabeled fluconazole in PBS (pH 7.0). For samples recovered at zero time, the cell suspension was chilled on ice for 30 min and then filtered after the addition of tritiated fluconazole. Cells were washed on the filters twice with 8 ml of PBS containing 100 µM unlabeled fluconazole. The filters were dried at 37°C for 1 h and placed in 10 ml of Hydrofluor scintillation fluid (National Diagnostics, Atlanta, Ga.). After overnight incubation at room temperature, the radioactivity was determined with a Packard (Downer's Grove, Ill.) 2200CA Tricarb liquid scintillation counter. The results are expressed as the counts per minute per 106 cells at 0 and 60 min.
Techniques and reagents.
C. glabrata genomic DNA was isolated from overnight cultures by using glass beads. DNA was sheared by multiple pipetting steps. C. glabrata RNA was isolated from logarithmic-phase cultures with a FastRNA Pro-Red kit (QBIOgene, Carlsbad, Calif.). Purified DNA fragments were recovered by use of a Geneclean II kit (Bio 101, Vista, Calif.). Hybond-N nylon membranes (Amersham, Arlington Heights, Ill.) were used for blot analyses. DNA probes were labeled with [
-32P]dCTP (Amersham Biosciences) by using a Prime-It II kit (Stratagene). DNA cloning and hybridization analyses were done by standard protocols (19). DNA sequencing was done with a DNA sequencing kit with a dRhodamine terminator (Applied Biosystems, Foster City, Calif.) and an automatic DNA sequencing system (Applied Biosystems).

RESULTS
Transposon mutant CgTn201S contains a disrupted CgERG1 gene.
One of the transposon mutants, CgTn201S, was unable to grow
on a MIN agar plate containing fluconazole at 100 µg/ml,
whereas host strain Cg1660 was able to grow. Genomic DNA from
CgTn201S was digested with BglII, self-ligated, and electroporated
into
E. coli; and the chloramphenicol-resistant clones were
analyzed. DNA contiguous to Tn
5<CmURA3> was sequenced.
A search of the GenBank database with the BLASTX algorithm found
sequence homology with
S. cerevisiae ERG1, which encodes a squalene
epoxidase of 496 amino acids. The full sequence of the
CgERG1 ORF was obtained from the Génolevures Consortium. Tn
5<Cm
URA3> was found to be inserted at the codon for amino acid
476 of
CgERG1 (data not shown).
Southern blot analysis with purified 2.9-kb Tn5<Cm URA3> as a probe detected a single 6.5-kb band in CgTn201S as well as in the rescued plasmid, pTn201S, while there was no signal in the parental strain, Cg1660 (Fig. 2B). A 2.2-kb CgERG1 probe detected 3.6- and 6.5-kb fragments in Cg1660 but hybridized only to the 6.5-kb fragments in CgTn201S (Fig. 2C). The 3.6-kb band was absent from CgTn201S. Together, Southern blotting and DNA sequence analyses indicated that CgERG1 is the gene targeted by the transposon in CgTn201S.
Increased expression of CgERG1 and CgERG11 in mutant CgTn201S.
To investigate whether the expression of CgERG1 was affected by the insertion of Tn5<Cm URA3>, the CgERG1 gene was used as a probe for Northern blot analysis. The CgERG1 probe detected a transcript with an expected size of about 1.5 kb in parental strain Cg1660 (Fig. 3A). Although no 1.5-kb transcript was found in mutant CgTn201S, the probe detected abundant transcripts of approximately 2 kb. The alteration in transcript size was likely due to a read-through transcript which included part of Tn5<Cm URA3>, which had been inserted into the 3' end of the CgERG1 ORF (Fig. 3A). To investigate the possibility of feedback regulation on the ergosterol biosynthetic pathway due to the defect in CgERG1, CgERG11 encoding an alpha-C-14-demethylase was also used as a probe for Northern blot analysis. The results show that the expression of CgERG11 is also up regulated in CgTn201S (Fig. 3B).
Accumulation of squalene and reduced ergosterol synthesis in CgTn201S.
Sterol analysis of aerobically grown cultures showed that the
level of accumulation of the sterol precursor, squalene, increased
dramatically in CgTn201S (Table
2). Squalene is the substrate
of squalene epoxidase, encoded by
ERG1. While squalene constitutes
only 1.6% of the total extractable sterols in Cg1660, squalene
comprises 66.6% of the total extractable sterols in CgTn201S.
The accumulation of squalene in CgTn201S suggested that squalene
epoxidation in ergosterol synthesis was impaired due to the
CgERG1 mutation in CgTn201S. The synthesis of ergosterol, which
constituted 32.9% of the total extractable sterols in CgTn210S,
was reduced but not abolished (63.7%) in Cg1660.
View this table:
[in this window]
[in a new window]
|
TABLE 2. Differences in levels of cholesterol uptake and sterol compositions of C. glabrata and C. albicans strains grown aerobically
|
Sterol supplements restored the growth defect of CgTn201S under conditions of low oxygen tension.
While CgTn201S grew slightly more slowly than Cg1660 under aerobic
conditions, growth under conditions of low oxygen tension (hypoxia)
required the presence of bovine serum or cholesterol (Fig.
4).
In contrast, both parental strain Cg1660 and a standard laboratory
strain, NCCLS84, grew slowly but well under conditions of low
oxygen tension.
CgTn201 had more efficient cholesterol uptake than wild-type C. glabrata and C. albicans strains.
Cholesterol is not synthesized by fungi, but both wild-type
C. glabrata strains tested, Cg1660 and NCCLS84, were able to
take up cholesterol from bovine serum-supplemented medium under
aerobic conditions, with the levels of uptake constituting 9.5
and 21.2% of total extractable sterols, respectively (Table
2). By comparison, two wild-type strains of
C. albicans, BWP17
and CAI4, showed negligible cholesterol uptake under the same
conditions. Strain CgTn201S was the most efficient at taking
up cholesterol from serum-containing medium, with the levels
of uptake constituting 34% of the total extractable sterols.
Altered drug susceptibility in CgTn201.
The susceptibilities to fluconazole, terbinafine, itraconazole, and amphotericin B were assessed in Cg1660, CgTn201S, and the CgERG1-complemented strain (CgTn201C) by using either MIN or RPMI medium (Table 3). CgTn201S was remarkably more susceptible to the sterol synthesis inhibitors fluconazole, itraconazole, and terbinafine; but there was a slight decrease in susceptibility to the sterol-binding antifungal amphotericin B. Complementation of CgTn201S with the CgERG1 gene restored the levels of susceptibility of the CgTn201C strain to the wild-type levels. As ergosterol constituted only 32.9% of the total extractable sterols in CgTn201S, whereas it constituted 63.7% in Cg1660 (Table 2), it is possible that fewer membrane ergosterol targets for amphotericin B led to the slight reduction in susceptibility to amphotericin B.
Sterol supplements reduced the fluconazole susceptibility of CgTn201S.
As determined by Etest, the fluconazole MIC for Cg1660 without
sterol was approximately 48 µg/ml under aerobic conditions,
while the fluconazole MIC for CgTn201S was dramatically reduced
to approximately 4 µg/ml and a distinct inhibition zone
was detected, in contrast to the fuzzy inhibition zone detected
for strain Cg1660 (Fig.
5). Addition of ethanol-Tween 80 without
sterol slightly increased the fluconazole susceptibilities of
both Cg1660 and CgTn201S. Sterol supplementation reduced the
fluconazole susceptibility of CgTn201S. No inhibition zone around
fluconazole strips was observed with CgTn201S or Cg1660 under
conditions of low oxygen tension and with exogenous ergosterol
or cholesterol.
CgTn201S had increased levels of uptake of rhodamine 6G and [3H]fluconazole.
Reduced ergosterol synthesis in CgTn201S could lead to an altered
membrane composition and altered permeability. Therefore, the
levels of both rhodamine 6G and [
3H]fluconazole accumulation
were analyzed to determine uptake efficiency. The accumulation
of rhodamine 6G, as determined by fluorescence cytometry, was
higher in strain CgTn201S than in strain Cg1660, with geometric
mean values of 26 and 13.9 arbitrary units, respectively (Fig.
6). In addition, four separate experiments demonstrated that
CgTn201S had much higher levels of [
3H]fluconazole uptake than
Cg1660, with the increases ranging from 5.4-fold (Fig.
7A) to
7.5-fold (data not shown). The increase in the level of [
3H]fluconazole
uptake in CgTn201S was consistent with the finding that CgTn201S
had higher levels of rhodamine 6G uptake.
CgERG1 complementation but not ergosterol supplementation reduced the levels of [3H]fluconazole uptake in CgTn201S.
Ergosterol supplementation was used to investigate the possibility
that membrane integrity could be restored to reduce the levels
of [
3H]fluconazole uptake. Neither Cg1660 nor CgTn201S showed
significant differences in the levels of [
3H]fluconazole accumulation
with exogenous ergosterol under aerobic conditions or under
low oxygen tension (Fig.
7A). In contrast, the
CgERG1-complemented
strain, CgTn201C, had a 3.5-fold reduction in the level of [
3H]fluconazole
accumulation (Fig.
7B). These results may indicate a quantitative
difference between the amount of ergosterol needed to restore
growth under conditions of low oxygen tension and the amount
needed to restore drug transport.

DISCUSSION
Transposon insertion into the coding region for the CgErg1p
C terminus decreased the level of but did not ablate ergosterol
synthesis. It is likely that an abnormal protein was formed,
judging from the increased size and abundance of the
CgERG1 transcript. As expected from a defective squalene epoxidase,
squalene accumulated in the mutant. Several phenotypic consequences
were unanticipated on the basis of previous studies of the
ERG1 mutations in
S. cerevisiae, a closely related species. The
S. cerevisiae ERG1 null mutant was not viable under aerobic conditions
and grew anaerobically only with addition of ergosterol to the
medium (
10). Aerobically viable
S. cerevisiae mutants have also
been reported. By mapping, the sequences of five of six different
erg1 mutants selected for terbinafine resistance under aerobic
conditions have been found to have single base changes in codons
402 to 433 of the 496 amino acids in
S. cerevisiae Erg1p (
9,
11). Squalene accumulated in mutant W/H10, and the level of
ergosterol synthesis was diminished in but not absent from W/H10
(
10). In CgTn201S, the
C. glabrata erg1 mutant reported here,
the
CgERG1 ORF was interrupted at codon 476, only 13 amino acids
from the carboxy terminus. The abundance of
CgERG1 and
CgERG11 mRNA in CgTn201S was increased significantly, which is likely
due to ergosterol feedback regulation. Unlike the
S. cerevisiae mutants, the susceptibilities of CgTn201S to terbinafine, itraconazole,
and fluconazole were increased. Additional findings for CgTn201S
were increased uptake of tritiated fluconazole and extremely
poor growth under conditions of low oxygen tension. Perhaps
mutant CgErg1p had a decreased efficiency of oxygen utilization.
The
Cgerg1 mutation in CgTn201S is unlikely to be a null mutation
because CgTn201S still synthesizes some ergosterol aerobically,
allowing aerobic growth of CgTn201S. In contrast, the poor growth
of CgTn201S under conditions of low oxygen tension is likely
due to the altered C terminus on CgErg1p, which requires high
levels of oxygen tension to function properly. Exogenous sterol
restored the growth of CgTn201S under conditions of low oxygen
tension but did not return the levels of [
3H]fluconazole uptake
to the levels for the wild type. Complementation of
CgERG1,
however, did decrease the levels of [
3H]fluconazole uptake nearly
to the levels for the wild type. The altered sterol composition
of CgTn201S may have interfered with drug transport, a defect
not sufficiently ameliorated by exogenous ergosterol, even under
conditions of low oxygen tension. Even though transport was
not restored by exogenous sterol in CgTn201S, fluconazole susceptibility
was reduced by exogenously added ergosterol or cholesterol under
aerobic conditions and was more dramatically reduced under conditions
of low oxygen tension (Fig.
5).
Decreased squalene epoxidation in CgTn210S can be inferred from the accumulation of squalene and the 50% reduction in the ergosterol content of CgTn201S. Decreased growth under hypoxic conditions and slower growth can be attributed to a decreased ergosterol content, on the basis of the ability of cholesterol-containing serum to restore both capacities. Complementation with a functioning copy of CgERG1 offered reassurance that the phenotypic changes in CgTn201S were due solely to changes in this one gene.
The ability of wild-type C. glabrata to incorporate cholesterol from serum under aerobic conditions has been noted previously (14). We confirmed the ability of C. glabrata to utilize exogenous cholesterol. Uptake of exogenous cholesterol was greatly enhanced by interruption of CgERG1 in our experiments and by the decreased expression of either CgERG9 or CgERG11 in the work of Nakayama et al. (14, 15). The antifungal mechanism of action of azoles is to block ergosterol synthesis. If wild-type C. glabrata were to take up sufficient cholesterol from host tissue, the chemotherapeutic effects of azoles could be impaired.

ACKNOWLEDGMENTS
M.B. is a recipient of a Burroughs Wellcome Fund Mycology Scholar
Award.

FOOTNOTES
* Corresponding author. Mailing address: Clinical Center, Room 11C304, NIH, Bethesda, MD 20892. Phone: (301) 496-3461. Fax: (301) 480-0050. E-mail:
Jbennett{at}niaid.nih.gov.


REFERENCES
1 - Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777.
2 - Botstein, D., S. C. Falco, S. E. Stewart, M. Brennan, S. Scherer, D. T. Stinchcomb, K. Struhl, and R. W. Davis. 1979. Sterile host yeasts (SHY): a eukaryotic system of biological containment for recombinant DNA experiments. Gene 8:17-24.[CrossRef][Medline]
3 - Castano, I., R. Kaur, S. Pan, R. Cregg, L. Penas Ade, N. Guo, M. C. Biery, N. L. Craig, and B. P. Cormack. 2003. Tn7-based genome-wide random insertional mutagenesis of Candida glabrata. Genome Res. 13:905-915.[Abstract/Free Full Text]
4 - Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.[Abstract]
5 - Geber, A., C. A. Hitchcock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. E. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.[Abstract]
6 - Hongay, C., N. Jia, M. Bard, and F. Winston. 2002. Mot3 is a transcriptional repressor of ergosterol biosynthetic genes and is required for normal vacuolar function in Saccharomyces cerevisiae. EMBO J. 21:4114-4124.[CrossRef][Medline]
7 - Izumikawa, K., H. Kakeya, H. F. Tsai, B. Grimberg, and J. E. Bennett. 2003. Function of Candida glabrata ABC transporter gene, PDH1. Yeast 20:249-261.[CrossRef][Medline]
8 - Kitada, K., E. Yamaguchi, and M. Arisawa. 1996. Isolation of a Candida glabrata centromere and its use in construction of plasmid vectors. Gene 175:105-108.[CrossRef][Medline]
9 - Klobucnikova, V., P. Kohut, R. Leber, S. Fuchsbichler, N. Schweighofer, F. Turnowsky, and I. Hapala. 2003. Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Biochem. Biophys. Res. Commun. 309:666-671.[CrossRef][Medline]
10 - Landl, K. M., B. Klosch, and F. Turnowsky. 1996. ERG1, encoding squalene epoxidase, is located on the right arm of chromosome VII of Saccharomyces cerevisiae. Yeast 12:609-613.[CrossRef][Medline]
11 - Leber, R., S. Fuchsbichler, V. V. Klobucnikova, N. Schweighofer, E. Pitters, K. Wohlfarter, M. Lederer, K. Landl, C. Ruckenstuhl, I. Hapala, and F. Turnowsky. 2003. Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 47:3890-3900.[Abstract/Free Full Text]
12 - Maesaki, S., P. Marichal, H. Vanden Bossche, D. Sanglard, and S. Kohno. 1999. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J. Antimicrob. Chemother. 44:27-31.[Abstract/Free Full Text]
13 - Molzahn, S. W., and R. A. Woods. 1972. Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae. J. Gen. Microbiol. 72:339-348.[Abstract/Free Full Text]
14 - Nakayama, H., M. Izuta, N. Nakayama, M. Arisawa, and Y. Aoki. 2000. Depletion of the squalene synthase (ERG9) gene does not impair growth of Candida glabrata in mice. Antimicrob. Agents Chemother. 44:2411-2418.[Abstract/Free Full Text]
15 - Nakayama, H., N. Nakayama, M. Arisawa, and Y. Aoki. 2001. In vitro and in vivo effects of 14-
-demethylase (ERG11) depletion in Candida glabrata. Antimicrob. Agents Chemother. 45:3037-3045.[Abstract/Free Full Text]
16 - National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17 - Parkinson, T., D. J. Falconer, and C. A. Hitchcock. 1995. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. 39:1696-1699.[Abstract]
18 - Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.[Abstract/Free Full Text]
19 - Sambrook, J., and W. Russell (ed.). 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
20 - Wilson, R. B., D. Davis, and A. P. Mitchell. 1999. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J. Bacteriol. 181:1868-1874.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, July 2004, p. 2483-2489, Vol. 48, No. 7
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.7.2483-2489.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Sionov, E., Chang, Y. C., Garraffo, H. M., Kwon-Chung, K. J.
(2009). Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence. Antimicrob. Agents Chemother.
53: 2804-2815
[Abstract]
[Full Text]
-
Chauhan, N., Kruppa, M., Calderone, R.
(2007). The Ssk1p Response Regulator and Chk1p Histidine Kinase Mutants of Candida albicans Are Hypersensitive to Fluconazole and Voriconazole. Antimicrob. Agents Chemother.
51: 3747-3751
[Abstract]
[Full Text]
-
Vandeputte, P., Tronchin, G., Berges, T., Hennequin, C., Chabasse, D., Bouchara, J.-P.
(2007). Reduced Susceptibility to Polyenes Associated with a Missense Mutation in the ERG6 Gene in a Clinical Isolate of Candida glabrata with Pseudohyphal Growth. Antimicrob. Agents Chemother.
51: 982-990
[Abstract]
[Full Text]
-
Ruckenstuhl, C., Lang, S., Poschenel, A., Eidenberger, A., Baral, P. K., Kohut, P., Hapala, I., Gruber, K., Turnowsky, F.
(2007). Characterization of Squalene Epoxidase of Saccharomyces cerevisiae by Applying Terbinafine-Sensitive Variants. Antimicrob. Agents Chemother.
51: 275-284
[Abstract]
[Full Text]
-
Tsai, H.-F., Krol, A. A., Sarti, K. E., Bennett, J. E.
(2006). Candida glabrata PDR1, a Transcriptional Regulator of a Pleiotropic Drug Resistance Network, Mediates Azole Resistance in Clinical Isolates and Petite Mutants.. Antimicrob. Agents Chemother.
50: 1384-1392
[Abstract]
[Full Text]
-
Liu, T. T., Lee, R. E. B., Barker, K. S., Lee, R. E., Wei, L., Homayouni, R., Rogers, P. D.
(2005). Genome-Wide Expression Profiling of the Response to Azole, Polyene, Echinocandin, and Pyrimidine Antifungal Agents in Candida albicans. Antimicrob. Agents Chemother.
49: 2226-2236
[Abstract]
[Full Text]
-
Pasrija, R., Krishnamurthy, S., Prasad, T., Ernst, J. F., Prasad, R.
(2005). Squalene epoxidase encoded by ERG1 affects morphogenesis and drug susceptibilities of Candida albicans. J Antimicrob Chemother
55: 905-913
[Abstract]
[Full Text]
-
Rogers, K. M., Pierson, C. A., Culbertson, N. T., Mo, C., Sturm, A. M., Eckstein, J., Barbuch, R., Lees, N. D., Bard, M.
(2004). Disruption of the Candida albicans CYB5 Gene Results in Increased Azole Sensitivity. Antimicrob. Agents Chemother.
48: 3425-3435
[Abstract]
[Full Text]